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The liver and metabolic health  
The liver plays a crucial regulatory role in the storage and distribution of lipids during fed and fasted 
states. With obesity, non-alcoholic fatty liver disease (NAFLD) often develops, a condition 
characterised by hepatic steatosis. Hepatic steatosis is the result of lipid input (from lipid uptake and 
de novo lipogenesis) exceeding lipid export (via β-oxidation, or VLDL and triglyceride secretion), 
resulting in net liver lipid accumulation. When present, hepatic steatosis can contribute to the 
development of other cardiometabolic diseases, such as type 2 diabetes and cardiovascular disease. 
It has been proposed that autonomic nervous system dysfunction is involved in the pathogenesis of 
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sympathetic and parasympathetic nerves. However, the importance of liver-brain signalling in the 
onset and/or the development of NAFLD has remained unclear. 
 
Liver sympathetic nerve activity and steatosis 
In the latest issue of the Journal of Physiology, Hurr et al. (2019) provided evidence to support a role 
for increased liver sympathetic nerve activity (SNA) in the development of hepatic steatosis in 
obesity. The authors used a 10 week high-fat diet (60% kcal from fat) to induce obesity and hepatic 
lipid accumulation in mice, which were compared to mice fed normal chow (with 5% kcal from fat). 
Multiunit recordings of liver SNA showed a ~2 fold increase in the obese mice with hepatic steatosis 
compared to normal chow-fed mice, which was mainly attributed to increased efferent nerve 
activity (the removal of afferent input was achieved by measuring nerve activity after sectioning the 
nerve distal to the recording site). The authors then utilised both whole-body (chemical denervation 
via the neurotoxin 6-OHDA) and liver specific methods (application of 10% phenol to the bundle of 
hepatic artery and portal vein) to inhibit liver SNA in the obese mice with hepatic steatosis. They 
showed that hepatic steatosis was alleviated in the treated versus the non-treated mice and this 
occurred despite no differential changes in body mass, energy or water intake, or energy 
expenditure. Interestingly, the inhibition of liver SNA in the chow-fed mice had no significant effect 
on liver lipid accumulation, suggesting that the increase in liver SNA following high-fat diet induced 
obesity is likely to be a homeostatic response to the energy and/or dietary lipid surplus.  
 
Hurr et al. (2019) also investigated potential mechanisms by which liver SNA may alter hepatic 
steatosis, using quantitative real time PCR to show that obese mice with hepatic steatosis exhibited 
an increased mRNA expression of proteins and transcription factors involved in hepatic lipid uptake 
and de novo lipogenesis. This upregulation of lipogenic genes was however mitigated by the 
inhibition of liver SNA. Proteins involved in lipid oxidation were also upregulated in obese mice with 
hepatic steatosis (versus chow-fed controls) but were not significantly altered by subsequent liver 
sympathetic denervation. Taken together, these findings suggest that increased liver SNA develops 
alongside high-fat diet induced obesity and that the inhibition of liver SNA may alleviate hepatic 
steatosis via lipid acquisition pathways. Consequently, interventions that alleviate the increase in 
liver SNA activity with obesity could help to reduce lipid accumulation in the liver and therefore offer 
benefits for NAFLD and associated cardiometabolic diseases. Whilst sympathetic nerve activity is 
important for regulating physiological processes in many tissues in healthy humans, the findings of 
Hurr et al. (2019) are in line with suggestions that for some tissues (e.g. skeletal muscle and the 
kidneys), an abnormal increase in SNA can have a role in cardiometabolic disease pathogenesis 
(Guarino et al., 2017).   
  
Experimental considerations 
In the work of Hurr et al. (2019), the increases in efferent nerve activity suggested that obesity‐
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mechanisms, of which increased hypothalamic neuropeptide Y (NPY) expression is a likely candidate 
(Bruinstroop et al., 2014). Alterations in SNA with diet-induced obesity could also be due to factors 
such as hyperinsulinemia, hyperleptinemia, increased angiotensin II levels, and/or baroreceptor 
dysfunction. These mechanisms could now also be explored to develop the research of Hurr et al. 
(2019). The authors also acknowledged that direct recordings of afferent liver SNA were needed to 
support their results. Indeed, greater fatty acid availability to the liver (due to the high-fat diet or 
heightened adipose tissue SNA and consequent increases in lipolysis) could have increased hepatic 
afferent signalling due to the lipid sensing role of the liver (Paolisso et al., 2000). This response is 
however likely to be achieved via the parasympathetic branch of the liver, and thus its contribution 
to global hepatic SNA is currently unclear (Paolisso et al., 2000). Measuring efferent and afferent 
liver SNA in combination with systemic lipid concentrations/hepatic lipid flux, and also investigating 
whether increases in SNA occur concomitantly across different tissues in obesity (or whether this 
response is first detected in specific tissues [e.g. in the adipose tissue before the liver]) would 
therefore be of interest. Another logical next step for this work would be to de-innervate the liver 
prior to the provision of a high-fat diet to further clarify the role of liver SNA in hepatic steatosis 
pathogenesis. This is important given the finding that hepatic steatosis in the obese mice was not 
completely reversed with either whole-body or liver-specific SNA inhibition, suggesting that hepatic 
steatosis may be a consequence of neural and non-neural mechanisms (although an intervention of 
>7 days may have resulted in a complete reversal of steatosis in the work of Hurr et al., 2019).  
  
Should we apply these results to humans?   
The authors also discussed research in obese Zucker rats where the surgical removal of liver 
sympathetic nerves did not alleviate hepatic steatosis. This suggests that the role of liver SNA in the 
development of metabolic disease may be specific to the research model employed and/or species 
studied. The distribution of sympathetic and parasympathetic nerves in the liver differs across 
species, including in mice and humans (Yi et al., 2010). Moreover, despite some genetic and 
physiological similarities between mice and humans, these species have evolved in different 
environments and differ in size, metabolic rate, sleep-wake cycles and feeding patterns. Whether 
the findings of Hurr et al. (2019) can be applied to humans is therefore unclear, but now warrants 
investigation. One potential next step would be to manipulate liver energy status in humans using 
diet (e.g. fructose and/or high-fat feeding) or exercise (to manipulate the liver glycogen content), 
which can be objectively measured using imaging techniques such as 13C nuclear magnetic 
resonance. When combined with measures of liver SNA, such as hepatic noradrenaline spillover rate 
or gall bladder contractility (Bruinstroop et al., 2014), this could provide some evidence that liver 
sympathetic signalling is associated with hepatic energy status in humans, at least in the short-term. 
Finally, although the increase in liver SNA in obesity may be locally maladaptive (i.e. manifesting as 
hepatic steatosis) this response may also help to protect other tissues. For example, an increased 
hepatic uptake of lipid could decrease systemic lipid concentrations, which may prevent ectopic 
storage in skeletal muscle (with benefits for insulin sensitivity) or cardiac tissue (which could help to 
preserve normal heart function) (Guarino et al., 2017). This would be in line with suggestions that 
increases in sympathetic nerve activity in some peripheral tissues (e.g. in skeletal muscle) is an 
adaptive (albeit futile) mechanism to increase resting energy expenditure in an attempt to maintain 
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Investigating the role of liver-brain signalling for metabolic diseases is certainly complex. Whilst 
autonomic nerve activity is altered in obesity, this involves tissue-specific changes in both afferent 
and efferent sympathetic and parasympathetic nerve activity. However, by combining different 
methods, the work of Hurr et al. (2019) provides novel insights into the role of liver SNA in the 
regulation of hepatic steatosis in mice with high-fat diet induced obesity and highlights a need to 
characterise liver autonomic nerve activity in the context of cardiometabolic diseases. Thus, whilst 
technically challenging, we should continue to pursue methods to measure and manipulate liver 
sympathetic signalling, as the research of Hurr et al. (2019) suggests that this may have implications 
for the development and/or treatment of cardiometabolic diseases. 
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